TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dosing of Ketorolac in the Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~\> 18 y/o~Exclusion Criteria:~pregnant allergic other contraindication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0 mg (Type: PLACEBO_COMPARATOR): 0 mg ketorolac - placebo
- 10 mg (Type: ACTIVE_COMPARATOR): 10 mg ketorolac - low dose ketorolac
- 30 mg (Type: ACTIVE_COMPARATOR): 30 mg ketorolac - usual dose ketorolac

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Epidural Fentanyl for 2nd Stage Labor Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Nulliparous women~2. Spontaneous labor~3. A single vertex presentation fetus at term (38-42 weeks)~4. Effective labor epidural analgesia with continuous epidural infusion established~5. Provide written consent to participate in the study.~Exclusion Criteria:~1. Multigravida women~2. Multigestation pregnancies~3. Patients being treated/managed for chronic pain~4. Allergies or significant adverse reactions to local anesthetic or opioid medications~5. Inadequate or unsatisfactory labor epidural analgesia~6. Patients with history of spine abnormalities or spine surgery~7. Non-English speaking~8. Prisoners~9. Age less than 18 years old

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose Fentanyl (Type: ACTIVE_COMPARATOR): Low dose epidural fentanyl combined with local anesthetic as 10mL of 0.125% bupivacaine with 20 mcg fentanyl (Fentanyl 20 mcg)
- High Dose Fentanyl (Type: EXPERIMENTAL): High dose epidural fentanyl combined with local anesthetic as 10mL of 0.125% bupivacaine with 100 mcg fentanyl (Fentanyl 100 mcg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Walking Interventions, Cognitive Remediation and Mild Cognitive Impairment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women meeting all criteria listed below will be included in the study:~* Subjects between 65-85 years of age inclusive~* Subjects with Short Physical Performance Battery of 10 or greater~* Subjects averaging less than 5,000 steps per day~* Subjects with Mini Mental State Exam 25-28, inclusive~* Subjects with normal for age physical-neurological exam~* Subjects able to walk a city block without a walking aid~* Written Informed Consent obtained PRIOR to performing any study procedures~Exclusion Criteria:~* Subjects with difficult walking due to pain or posture~* Subjects with difficulty in using computer due to significant visual and/or fine motor impairment~* Subjects with large weight loss (\>15 Kilogram) in the last 12 months~* Subjects with geriatric depression scale \> 9.~* Subjects with Malignancies in the past 5 years, with the exception of skin cancer therapeutically controlled~* Subjects with abnormal electrocardiogram results. These include: a resting heart rate below 40 bpm or above 100 bpm, previously unknown and/or untreated atrial fibrillation or flutter, evidence of a third degree A-V block, a previously undocumented left bundle branch block, S-T segment depression of greater than 2 mm, evidence of a previous MI, or any other findings that in the clinical judgment of the medical investigator preclude participation in an exercise intervention.~* Subjects with shortness of breath, exertional angina, uncontrolled high blood pressure or any other chronic medical condition deemed by the physician to preclude participation in an exercise intervention.~* Subjects with any other medical condition or disease that is life-threatening or that can interfere with, or be aggravated by, exercise.~* Subjects who currently smoke.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Cognitive Remediation Therapy Group (Type: EXPERIMENTAL): 30 minute Cognitive Remediation Therapy and 60 minute Healthy Living Class three time per week
- Walking Intervention Group (Type: EXPERIMENTAL): 60 minutes of walking and 30 minutes of reading stimulation three times a week
- Combination Group (Type: EXPERIMENTAL): 30 minutes of Cognitive Remediation therapy and 60 minutes of walking three times a week
- Healthy Living Group (Type: EXPERIMENTAL): 60 minute Healthy Living Class and 30 minutes of reading stimulation three times a week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Energy Consumption and Cardiorespiratory Load During Walking With and Without Robot-Assistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Stroke patients with a lower limb motor impairment~* Time since stroke \< 1 year~* ≥ 18 years~* \< 193 cm~* \< 135kg~* Able to walk overground (body-weight support allowed if necessary) for at least 10 minutes at a comfortable walking speed~Exclusion Criteria:~* Contra-indications for exercise testing according to the American College of Sports Medicine~* Musculoskeletal problems (other than stroke) affecting the ability to walk~* Concurrent pulmonary diseases~* Concurrent neurological diseases~* Communicative and/or cognitive problems affecting the ability to comprehend or follow instructions~* Other problems that affect the execution of the interventions, e.g. severe spasticity, contractures or dermatologic contraindications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lokomat - Treadmill - Overground (Type: EXPERIMENTAL): Walking order: lokomat walking, treadmill walking, overground walking
- Lokomat - Overground - Treadmill (Type: EXPERIMENTAL): Walking order: lokomat walking, overground walking, treadmill walking
- Treadmill - Lokomat - Overground (Type: EXPERIMENTAL): Walking order: treadmill walking, lokomat walking, overground walking
- Treadmill - Overground - Lokomat (Type: EXPERIMENTAL): Walking order: treadmill walking, overground walking, lokomat walking
- Overground - Lokomat - Treadmill (Type: EXPERIMENTAL): Walking order: overground walking, lokomat walking, treadmill walking
- Overground - Treadmill - Lokomat (Type: EXPERIMENTAL): Walking order: overground walking, treadmill walking, lokomat walking

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cardiac MRI Biomarker Testing (GCC 1618)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Breast cancer patients who are undergoing internal mammary lymph node radiation which is the investigators institutional policy for patients with axillary lymph node involvement~* Clinical AJCC (AJCC, 7th ed.) II, IIIA or IIIB with non-operable disease or those who refuse surgery who are recommended concurrent chemoradiation. Patients who present with N2 or N3 disease and an undetectable NSCLC primary tumor are eligible.~* Any lung cancer, thymic cancer or mesothelioma patient getting either chemoradiation or radiation alone wherein heart gets radiation exposure~* Patients who have received systemic treatment (up to 4 cycles of induction chemotherapy, or up to 6 months of targeted therapy) and are rendered candidate for concurrent chemoradiation are also eligible~* Patients with recurrent disease overlapping or in close proximity to heart getting hypofractionated or conventionally fractionated proton therapy alone.~* Intensity modulated radiotherapy, 3-D conformal radiotherapy, electron radiotherapy, and proton radiotherapy will be permitted.~* Patients who develop local or nodal recurrence after surgery and rendered candidate for definitive concurrent chemoradiation are also eligible.~* The patient must give protocol-specific consent on an IRB approved consent form prior to completion of protocol specific testing/procedures.~* 18 years of age or older.~Exclusion Criteria:~* Pregnant/breast feeding patients or those not willing to undertake contraception if of child-producing potential while on study~* Patients with Stage IV disease~* Patients with contraindications to MRI examination (e.g. gadolinium allergies/reactions, metallic implants, incompatible implanted electronic/cardiac devices, over scanner weight tolerance etc.)~* Patients with hepatorenal syndrome~* Patients with Chronic Kidney Disease defined as eGFR \<30 ml/min~* Patients unable to lie supine for 30 minutes for MRI examination~* Patients having undergone prior radiation therapy to the chest

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Breast Cancer (Type: None): Breast cancer patients who are undergoing internal mammary lymph node radiation
- Lung Cancer, thymic cancer or mesothelioma (Type: None): Non-surgical Stage III non-small cell lung cancer patients undergoing mediastinal nodal irradiation with curative intent using concurrent chemotherapy~Any lung cancer, thymic cancer or mesothelioma patient getting either chemoradiation or radiation alone wherein heart gets radiation exposure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Verapamil in Chronic Rhinosinusitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients presenting to the Massachusetts Eye and Ear Sinus Center~2. Age 18-80 yrs old~3. Diagnosed with Chronic Rhinosinusitis with Nasal Polyps according to the EPOS 2012 consensus criteria~Exclusion Criteria:~1. Patients with the following comorbidities:~   * GI Hypomotility~  * Heart Failure~  * Liver Failure~  * Kidney Disease~  * Muscular Dystrophy~  * Pregnant or Nursing Females~  * Steroid Dependency~2. Patients taking the following medications:~   * Aspirin~  * Beta-blockers~  * Cimetidine(Tagamet)~  * Clarithromycin(Biaxin)~  * Cyclosporin~  * Digoxin~  * Disopyramide(Norpace)~  * Diuretics~  * Erythromycin~  * Flecainide~  * HIV Protease Inhibitors(Indinavir, Nelfinavir, Ritonavir)~  * Quinidine~  * Lithium~  * Pioglitazone~  * Rifampin~  * St Johns Wort~3. Patients with cardiac or conduction abnormality picked up by screening EKG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Verapamil HCl, capsules for oral administration, 80mg, TID, for 8 weeks
- Control (Type: PLACEBO_COMPARATOR): Placebo, capsules for oral administration, TID, for 8 weeks
- Open Label (Type: EXPERIMENTAL): Verapamil HCl, capsules for oral administration, 80mg, TID, for 1 year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use of Neural Functional Electrical Stimulation for the Recovery of Grasping Movements for Patient With Quadriplegia.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Neurological level ≥ C7~2. 18 years old min and max 65 years old,~3. Complete traumatic injury: defined by A or B score on the AIS scale.~4. patient belonging to group 0 or 1 of the Giens classification.~5. neurological stability (no change in muscle testing)\> 6 months,~6. post-injury duration\> 6 months~7. Patients undergoing surgery to restore elbow extension.~8. threshold of stimulation and diffusion of the studied muscles below 50 mA of intensity for a pulse width of 300 μs and a frequency of 25 Hz.~9. positive electrical mapping of muscles with a minimum score of 4 MRC for at least one of the extensors (triceps, ECRL, ECRB, EDC, EPL) and / or flexor (FPL, FDS, FDP).~Exclusion Criteria:~* 1. strong spasticity and contractures in flexion or extension of the upper limbs.~  2. Unstable epilepsy. 3. Unstable cardiovascular pathology (coronary heart disease, major hypertension, heart failure etc.).~  4. wearing a pacemaker. 5. Dermatological problems contraindicate the application of surface electrodes.~  6. body weight\> 100kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Instillation of Gemcitabine in Patients With Superficial Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical evidence of superficial transitional cell carcinoma of the bladder~* Males or females at least 18 years of age~* Karnofsky Performance Status greater than or equal to 70%~* Patient compliance and geographic proximity that allow adequate follow-up~* Female patients with reproductive potential must use a reliable contraceptive method if appropriate (for example, intrauterine device \[IUD\], birth control pills, or barrier device) during the study. Female patients with reproductive potential must have a negative serum pregnancy test within 7 days of study enrollment.~* Signed informed consent.~Exclusion Criteria:~* Clinical evidence of muscle-invasive or locally advanced bladder cancer~* Clinical evidence of upper urinary tract tumor~* Distant metastases~* Other malignancies within the last 2 years, except non-melanotic skin tumors, carcinoma in situ of the cervix or organ-confined prostate cancer after curative therapy~* Severe concomitant psychiatric disease~* Febrile, active infection~* Other serious concomitant disorders that would compromise the safety of the patient or his/her ability to complete the study according to the protocol, at the discretion of the investigator (for example, unstable angina pectoris, uncontrolled diabetes mellitus)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Heat Intolerance in the Group of FMF Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* double mutations MEFV~* mail~* age from 18 to 30~* colchicine treatment~* absence of attack during 2 months~Exclusion Criteria:~* individual wish

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- FMF patients (Type: None): 15 FMF patients with double mutations MEFV, mail sex, from the age from 18 to 30. treated with colchicine, without attacks not less than 2 months
- healthy people (Type: None): Healthy individuals, that participated in the study of Heller Institute of Medical Research.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of the Use of Tissue Plasminogen Activator (tPA) in Intra-Abdominal Collections in Children - A Prospective Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All patients under the age of 18 years with intra-abdominal bacterial abscesses requiring percutaneous drain insertion (including transrectal drains).~2. Drain(s) must be inserted within the 23hrs prior to enrollment in the study.~3. The underlying diagnosis of the condition will not affect the enrollment of the patient unless it is detailed within the exclusion criteria (section 4.1.2).~4. Patients and parents must have signed informed consent to participate in the study.~Exclusion Criteria:1.~1. Pancreatic abscess (not bacterial in nature)~2. Known coagulation impairment~3. Known central nervous system tumor or abscesses~4. Arteriovenous malformation~5. Aneurysm or history of central nervous system bleeding~6. Hypersensitivity to tPA~7. Recent administration of an investigational drug (within previous 30 days)~8. Pregnancy~9. Breast-feeding~10. Fulminant hepatic failure~11. Proven fistula (as it will alter the drainage time) or any abscess secondary to Crohn's Disease (because fistula existence cannot be excluded)~12. Necrotizing enterocolitis~13. Children requiring 4 or more drains

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- tPA (Type: EXPERIMENTAL): tissue Plasminogen Activator
- Placebo (Type: PLACEBO_COMPARATOR): Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ketogenic Dietary Patterns in Young Adults and Kidney Health

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Overweight (BMI 25-30 kg/m2)~* Weight stable for last 4 weeks by self-report~* Residing in the greater Charlottesville/Albemarle area for \>6 months out of the last year~* Normal kidney function at baseline, eGFR ≥60 ml/min/1.73m2 and UACR \<30 mg/g at screening~Exclusion Criteria:~* History of major medical comorbidities by self-report (history of diabetes; diagnosed kidney disease; diagnosed gastrointestinal disorders including inflammatory bowel disease, gastric bypass, intestinal resection, celiac disease or other malabsorption; esophageal or other disorders limiting ability to swallow food)~* Systolic blood pressure \>160 or \<100 at screening~* Daily use of diuretics such as hydrochlorothiazide~* Serum potassium \<3.5 or \>5.1 mEq/L at screening~* Serum magnesium \<1.6 mg/dL at screening~* Serum sodium \<135 or \>149 mEq/L at screening~* HbA1c \> 6.5% at screening~* Fasting plasma glucose \> 126 mg/dL at screening~* Pregnant or breastfeeding women (confirmed by spot urine at screening)~* Inability to give written informed consent in English~* Inability to walk up to 1 mile at a slow pace between buildings for study visits~* Food allergies~* Eating ketogenic or low carbohydrate diet over last 4 weeks~* Blood ketones positive at screening~* Intolerance or dislike of any study foods limiting adherence~* Inability to attend daily visits~* Vulnerable population such as direct reports or students of the investigators~* Lack of access to refrigeration or equipment to safely reheat meals

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Ketogenic Diet (Type: EXPERIMENTAL): Subjects will be provided with foods following a ketogenic diet for 15 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Tilburg Vasospasm Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* spontaneous subarachnoid hemorrhage (SAH) with aneurysmal pattern graded as a Fisher grade III or higher on cerebral CT-scan.~* CSF drainage by external lumbar catheter can start within 96 hours after the initial SAH~* the drainage can start prior to the treatment of the ruptured aneurysm~* informed consent is signed by the patient or his representative~Exclusion Criteria:~* spontaneous SAH with aneurysmal pattern graded as a Fisher grade I or II on CT and perimesencephalic hemorrhages~* traumatic SAH~* symptomatic hydrocephalus on admission necessitating drainage (EVD or ELD)~* the presence of a large intraventricular bloodclot in the third or fourth ventricle on CT~* the presence of a mass lesion with significant cerebral midline shift~* all patients whose neurological condition is too poor to allow clinical recognition of signs and symptoms of cerebral vasospasm. This includes all patients with a Hunt and Hess Grade V who failed to improve after initial resuscitation~* no informed consent~* mycotic aneurysms

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- external lumbar drainage (Type: ACTIVE_COMPARATOR): Within 96 hours of initial subarachnoid hemorrhage, patients were randomized for external lumbar drainage (ELD)of cerebrospinal fluid during a maximum of 7 days or standard treatment of subarachnoid hemorrhage without ELD
- No intervention (Type: NO_INTERVENTION): In this arm the patients received standard treatment following protocol for patients with subarachnoid hemorrhage

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues